FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070080644> ?p ?o ?g. }

• W2070080644 endingPage "297" @default.
• W2070080644 startingPage "297" @default.
• W2070080644 abstract "Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation Ibrahim Gueler,1 Susanne Mueller,1 Matthias Helmschrott,1 Christian U Oeing,1 Christian Erbel,1 Lutz Frankenstein,1 Christian Gleißner,1 Arjang Ruhparwar,2 Philipp Ehlermann,1 Thomas J Dengler,3 Hugo A Katus,1 Andreas O Doesch1 1Department of Cardiology, University of Heidelberg, Heidelberg, 2Department of Cardiac Surgery, University of Heidelberg, Heidelberg, 3Department of Cardiology, SLK-Kliniken Heilbronn, Bad Friedrichshall, Germany Background: Type 2 Diabetes mellitus (T2DM) is a common comorbidity in patients after heart transplantation (HTx) and is associated with adverse long-term outcomes. Methods: The retrospective study reported here analyzed the effects of vildagliptin therapy in stable patients post-HTx with T2DM and compared these with control patients for matched-pairs analysis. A total of 30 stable patients post-HTx with T2DM were included in the study. Fifteen patients (mean age 58.6 ± 6.0 years, mean time post-HTx 4.9 ± 5.3 years, twelve male and three female) were included in the vildagliptin group (VG) and 15 patients were included in the control group (CG) (mean age 61.2 ± 8.3 years, mean time post-HTx 7.2 ± 6.6 years, all male). Results: Mean glycated hemoglobin (HbA1c) in the VG was 7.4% ± 0.7% before versus 6.8% ± 0.8% after 8 months of vildagliptin therapy (P = 0.002 vs baseline). In the CG, HbA1c was 7.0% ± 0.7% versus 7.3% ± 1.2% at follow-up (P = 0.21). Additionally, there was a significant reduction in mean blood glucose in the VG, from 165.0 ± 18.8 mg/dL to 147.9 ± 22.7 mg/dL (P = 0.002 vs baseline), whereas mean blood glucose increased slightly in the CG from 154.7 ± 19.7 mg/dL to 162.6 ± 35.0 mg/dL (P = 0.21). No statistically significant changes in body weight (from 83.3 ± 10.8 kg to 82.0 ± 10.9 kg, P = 0.20), total cholesterol (1.5%, P = 0.68), or triglyceride levels (8.0%, P = 0.65) were seen in the VG. No significant changes in immunosuppressive drug levels or dosages were observed in either group. Conclusion: Vildagliptin therapy significantly reduced HbA1c and mean blood glucose levels in post-HTx patients in this study with T2DM and did not have any negative effects on lipid profile or body weight. Thus, vildagliptin therapy presented an interesting therapeutic approach for this selected patient cohort. Keywords: immunosuppression, glycated hemoglobin, mean blood glucose" @default.
• W2070080644 created "2016-06-24" @default.
• W2070080644 creator A5007336095 @default.
• W2070080644 creator A5015522977 @default.
• W2070080644 creator A5020918009 @default.
• W2070080644 creator A5027876138 @default.
• W2070080644 creator A5032480152 @default.
• W2070080644 creator A5049262839 @default.
• W2070080644 creator A5051724581 @default.
• W2070080644 creator A5054288936 @default.
• W2070080644 creator A5067336736 @default.
• W2070080644 creator A5076243523 @default.
• W2070080644 creator A5081755430 @default.
• W2070080644 creator A5084693309 @default.
• W2070080644 date "2013-04-01" @default.
• W2070080644 modified "2023-09-25" @default.
• W2070080644 title "Effects of vildagliptin (Galvus&reg;) therapy in patients with type 2 diabetes mellitus after heart transplantation" @default.
• W2070080644 cites W1960382620 @default.
• W2070080644 cites W1967477040 @default.
• W2070080644 cites W1969389642 @default.
• W2070080644 cites W1970406523 @default.
• W2070080644 cites W1977619586 @default.
• W2070080644 cites W1978744165 @default.
• W2070080644 cites W1984588810 @default.
• W2070080644 cites W1991565451 @default.
• W2070080644 cites W2000083483 @default.
• W2070080644 cites W2027249582 @default.
• W2070080644 cites W2033493723 @default.
• W2070080644 cites W2033661046 @default.
• W2070080644 cites W2036167841 @default.
• W2070080644 cites W2039779698 @default.
• W2070080644 cites W2042587216 @default.
• W2070080644 cites W2043121816 @default.
• W2070080644 cites W2043652905 @default.
• W2070080644 cites W2047353065 @default.
• W2070080644 cites W2049323977 @default.
• W2070080644 cites W2050475203 @default.
• W2070080644 cites W2064900976 @default.
• W2070080644 cites W2069150029 @default.
• W2070080644 cites W2074925580 @default.
• W2070080644 cites W2092827562 @default.
• W2070080644 cites W2092838310 @default.
• W2070080644 cites W2115428578 @default.
• W2070080644 cites W2137471483 @default.
• W2070080644 cites W2140369318 @default.
• W2070080644 cites W2152978153 @default.
• W2070080644 cites W2167621077 @default.
• W2070080644 cites W2168552871 @default.
• W2070080644 cites W2178920245 @default.
• W2070080644 cites W2402672416 @default.
• W2070080644 doi "https://doi.org/10.2147/dddt.s43092" @default.
• W2070080644 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3623547" @default.
• W2070080644 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23630415" @default.
• W2070080644 hasPublicationYear "2013" @default.
• W2070080644 type Work @default.
• W2070080644 sameAs 2070080644 @default.
• W2070080644 citedByCount "9" @default.
• W2070080644 countsByYear W20700806442015 @default.
• W2070080644 countsByYear W20700806442017 @default.
• W2070080644 countsByYear W20700806442018 @default.
• W2070080644 countsByYear W20700806442021 @default.
• W2070080644 countsByYear W20700806442022 @default.
• W2070080644 crossrefType "journal-article" @default.
• W2070080644 hasAuthorship W2070080644A5007336095 @default.
• W2070080644 hasAuthorship W2070080644A5015522977 @default.
• W2070080644 hasAuthorship W2070080644A5020918009 @default.
• W2070080644 hasAuthorship W2070080644A5027876138 @default.
• W2070080644 hasAuthorship W2070080644A5032480152 @default.
• W2070080644 hasAuthorship W2070080644A5049262839 @default.
• W2070080644 hasAuthorship W2070080644A5051724581 @default.
• W2070080644 hasAuthorship W2070080644A5054288936 @default.
• W2070080644 hasAuthorship W2070080644A5067336736 @default.
• W2070080644 hasAuthorship W2070080644A5076243523 @default.
• W2070080644 hasAuthorship W2070080644A5081755430 @default.
• W2070080644 hasAuthorship W2070080644A5084693309 @default.
• W2070080644 hasBestOaLocation W20700806441 @default.
• W2070080644 hasConcept C126322002 @default.
• W2070080644 hasConcept C134018914 @default.
• W2070080644 hasConcept C164705383 @default.
• W2070080644 hasConcept C197934379 @default.
• W2070080644 hasConcept C2776453732 @default.
• W2070080644 hasConcept C2777180221 @default.
• W2070080644 hasConcept C2777538456 @default.
• W2070080644 hasConcept C2778198053 @default.
• W2070080644 hasConcept C2778774980 @default.
• W2070080644 hasConcept C2778849806 @default.
• W2070080644 hasConcept C2910068830 @default.
• W2070080644 hasConcept C2911091166 @default.
• W2070080644 hasConcept C555293320 @default.
• W2070080644 hasConcept C71924100 @default.
• W2070080644 hasConceptScore W2070080644C126322002 @default.
• W2070080644 hasConceptScore W2070080644C134018914 @default.
• W2070080644 hasConceptScore W2070080644C164705383 @default.
• W2070080644 hasConceptScore W2070080644C197934379 @default.
• W2070080644 hasConceptScore W2070080644C2776453732 @default.
• W2070080644 hasConceptScore W2070080644C2777180221 @default.
• W2070080644 hasConceptScore W2070080644C2777538456 @default.
• W2070080644 hasConceptScore W2070080644C2778198053 @default.

• next